Therapeutics News and Research

RSS

Four USF professors selected as AIMBE College of Fellows

Four University of South Florida professors have been elected to the 2016 College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE): Cesario Borlongan and Shyam Mohapatra from the USF Morsani College of Medicine, USF Health; and Robert Frisina, Jr., and Sudeep Sarkar from the USF College of Engineering.

20 Jan 2016

GBI Research says COPD therapeutics pipeline lacks innovation

Analysis from business intelligence provider GBI Research - Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation - states that while currently-available drugs aim to manage the frequency and severity of symptoms associated with COPD, none have been shown to modify long-term disease progression.

19 Jan 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Oncolytics Biotech Inc. today announced that the first patients have been treated in a Phase 1b study of pembrolizumab (KEYTRUDA) in combination with REOLYSIN (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).

19 Jan 2016

Johns Hopkins study shows high doses of cocaine kill brain cells

Working with mice, researchers at Johns Hopkins have contributed significant new evidence to support the idea that high doses of cocaine kill brain cells by triggering overactive autophagy, a process in which cells literally digest their own insides. Their results, moreover, bring with them a possible antidote, an experimental compound dubbed CGP3466B.

19 Jan 2016

Researchers reveal biological connection between obesity and colorectal cancer risk

Obesity has long been associated with increased risk of colorectal cancer, but the link has never been understood. Now, a research team led by investigators at Thomas Jefferson University has revealed the biological connection, and in the process, has identified an approved drug that might prevent development of the cancer.

18 Jan 2016

Findings offer potential new therapeutic target to boost strength of heart muscle contractions

Researchers at UT Southwestern Medical Center have identified a previously unrecognized small protein in cells of the human heart that plays a key role in heart muscle contraction. The protein is made from an RNA that was previously believed to be a blank or non-coding RNA, suggesting there may be many other small 'non-coding' segments that play important biological roles.

18 Jan 2016

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself.

13 Jan 2016

TSRI scientists receive $2.1 million NIH grant to create new library of drug candidates

Scientists at The Scripps Research Institute have received a grant of more than $2.1 million from the National Institutes of Health's National Institute of General Medical Sciences to create and screen a new library of drug candidates.

13 Jan 2016

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

Sorrento Therapeutics, Inc., an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer and other unmet medical needs, announced today that it has formed an exclusive partnership with the world-renowned Karolinska Institutet in Stockholm, Sweden, to perform cutting-edge immuno-oncology research and to develop new natural killer (NK) cell-based therapies.

11 Jan 2016

UA researchers find genetic mutations associated with respiratory disease

Asthma affects more than 278 million people worldwide and can lead to serious consequences later in life. While current approved therapies address symptoms, they do not halt disease progression.

11 Jan 2016

Wyss Institute scientists develop better assay for testing hemostasis

Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University have devised a better assay for testing blood's clotting tendency, also known as hemostasis, which could one day prove lifesaving in a variety of clinical situations in which a patient's health is jeopardized by abnormal blood coagulation and platelet function.

11 Jan 2016

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, the University of Birmingham and Cancer Research Technology, the commercialisation arm of Cancer Research UK, announces today the launch of a collaboration to develop a new immuno-oncology cellular therapy based on gene modifying T cells to target solid tumours.

8 Jan 2016

QT Vascular reports initial results from first-in-human study of Chocolate Heart drug-coated balloon

QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"), a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease, announce today the release of the initial results from the first-in-human study of its unique drug-coated balloon, Chocolate Heart.

7 Jan 2016

Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

The conclusion drawn from a recent study that insertion of adeno-associated virus 2 (AAV2) into human DNA causes mutations leading to the development of hepatocellular carcinoma (HCC) was resoundingly rejected by leading researchers in the fields of gene therapy and molecular genetics.

7 Jan 2016

Common antibiotics can promote C. diff infections by killing off bile acid-altering microbes

New research from North Carolina State University and the University of Michigan finds that bile acids which are altered by bacteria normally living in the large intestine inhibit the growth of Clostridium difficile, or C. diff. C. diff is a harmful bacterium that can cause painful and sometimes fatal infections.

7 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI).

6 Jan 2016

Vanderbilt-led study questions about reporting genetic results to patients

A genetic test that suggests a patient may be at increased risk for potentially fatal heart rhythms is very often not as ominous as it sounds.

6 Jan 2016

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Millendo Therapeutics, a University of Michigan startup company, announced an exclusive license agreement with AstraZeneca for the worldwide development and commercialization rights to test a new compound, MLE4901, for the treatment of polycystic ovary syndrome.

6 Jan 2016

Therapeutics News and Research

Four USF professors selected as AIMBE College of Fellows

GBI Research says COPD therapeutics pipeline lacks innovation

CASI Pharmaceuticals receives $10.3 million in strategic financing

First patients treated in Phase 1b trial of pembrolizumab with REOLYSIN in advanced pancreatic adenocarcinoma

Johns Hopkins study shows high doses of cocaine kill brain cells

Researchers reveal biological connection between obesity and colorectal cancer risk

Findings offer potential new therapeutic target to boost strength of heart muscle contractions

Researchers reveal totally new biological mechanism that underlies cancer

TSRI scientists receive $2.1 million NIH grant to create new library of drug candidates

Sorrento, Karolinska Institutet partner to develop new NK cell-based therapies

UA researchers find genetic mutations associated with respiratory disease

Wyss Institute scientists develop better assay for testing hemostasis

New project aims to develop CAR-T cell immuno-oncology cellular therapy for solid tumours

QT Vascular reports initial results from first-in-human study of Chocolate Heart drug-coated balloon

Leading researchers reject proposed link between adeno-associated virus 2 and hepatocellular carcinoma

Common antibiotics can promote C. diff infections by killing off bile acid-altering microbes

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

Vanderbilt-led study questions about reporting genetic results to patients

Millendo signs license agreement, secures funding to test new drugs for treatment of endocrine disorders

Industry Focus eBook - Biotechnology (4th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News